Regulation of oxidative stress in Alzheimer model mice and its application for treatment
Description: It is recognized that increased oxidative damage on neurons is an early event in Alzheimer's disease (AD). Galantamine is one of acetylcholinesterase inhibitors and has an allosteric potentiating ligand function for nicotinic acetylcholine receptors. We showed that earlier treatment (before the appearance of Aβ plaques) of galantamine results in the improvement of cognitive function and suppresses the oxidative stress and the progression of pathological findings in AD mice. Bone marrow mesenchymal stem cell (BMSC)-treatment improved spatial memory impairment and reduced Aβ plaques deposition and Aβ1-42 levels of soluble fraction of brain homogenates in AD mice. The oxidative stress in the BMSC-treated mouse brain were also ameliorated. These findings suggest that galantamine and BMSC may prevent the progression of AD pathology by controlling oxidative stress and excessive Aβ deposition.
Amount: ¥17,290,000
Funding type: research
Funder scheme: Grant-in-Aid for Scientific Research (B)
Start date: 2016-04-01
End date: 2019-03-31
Investigator: Shun Shimohama
Institution: Sapporo Medical University
Funded outputs count: 7
Funder award ID: 16H05279
OpenAlex ID: G4894412129